U.S. Markets closed

Judge Finds Akorn's Miscues Justified Fresenius Exit From Deal

Oct.01 -- Fresenius SE had proper grounds for canceling a $4.3 billion buyout of rival drugmaker Akorn Inc. and doesn’t need to consummate the deal, a judge said in a ruling that comes as a blow to Akorn investors. Bloomberg's Ed Hammond has more on "Bloomberg Markets: The Close."